An update on current management of advanced renal cell cancer, biomarkers, and future directions.
Ann Cancer Res
; 1(2): 1-10, 2014.
Article
em En
| MEDLINE
| ID: mdl-25722991
ABSTRACT
In the past decade, metastatic renal cell carcinoma (mRCC) treatment underwent significant advancement that resulted in an unprecedented improvement in the prognosis of this disease. This review will provide an updated review of currently approved treatment options, namely antiangiogenic and immunotherapy, as well as treatment guideline recommended by the National Comprehensive Cancer Network (NCCN). We will summarize studies ongoing in determining prognostic and predictive biomarkers in maximizing therapeutic benefit in the treatment of this disease. Lastly, we will discuss promising agents in clinical testing.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Guideline
Idioma:
En
Revista:
Ann Cancer Res
Ano de publicação:
2014
Tipo de documento:
Article